Last edition
News about "AstraZeneca"
Alembic Pharmaceuticals Secures USFDA Approval for Ticagrelor Tablets, 60 mg
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg. The product is therapeutically equivalent to Brilinta Tablets, 60 mg, from AstraZeneca.
AstraZeneca | 29/10/2025 | By Dineshwori
AstraZeneca opens expanded manufacturing facility in Texas
AstraZeneca’s USD 445 million investment will support global manufacturing of Lokelma
AstraZeneca | 16/10/2025 | By Dineshwori
AstraZeneca India to Launch Hyperkalaemia Treatment Lokelma in November 2025
AstraZeneca Pharma India Limited (AZPIL) has announced the upcoming launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in India in November 2025.
AstraZeneca | 15/10/2025 | By Dineshwori | 195
AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while strengthening the nation’s biopharmaceutical innovation base.
AstraZeneca | 11/10/2025 | By Dineshwori
New manufacturing facility to be located near Charlottesville, in Albemarle County, Virginia will develop and manufacture a broader range of medicines including weight management, metabolic and cancer technologies.<br />
AstraZeneca | 10/10/2025 | By Dineshwori
Turbine Partners with AstraZeneca to Accelerate Antibody-Drug Conjugate Discovery
Turbine, a leading company specialising in virtualising biological experiments through artificial intelligence (AI), has announced a new collaboration with AstraZeneca to enhance the discovery of antibody-drug conjugates (ADCs).
AstraZeneca | 09/10/2025 | By Dineshwori | 117
AstraZeneca Partners with Algen Biopharmaceuticals in USD 555 Million Gene Therapy Deal
AstraZeneca has entered into a collaboration and licence agreement valued at up to USD 555 million with United States–based biotechnology company Algen Biopharmaceuticals to develop gene therapies targeting rare diseases.
AstraZeneca | 07/10/2025 | By Darshana | 129
CDSCO approves AstraZeneca's Trastuzumab Deruxtecan for More HER2-Positive Tumours
With this, Trastuzumab Deruxtecan becomes India’s first Antibody Drug Conjugate (ADC) approved for a tumour-agnostic indication.
AstraZeneca | 04/10/2025 | By Dineshwori | 176
US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer
The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.
AstraZeneca | 25/09/2025 | By Dineshwori
AstraZeneca Rolls Out Anti-Complement Therapy for aHUS and PNH
AstraZeneca India launches Eculizumab (300 mg, 10 mg/ml), the first approved anti-complement therapy in India for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH), following CDSCO approval in January 2025 for import, sale and distribution.
AstraZeneca | 09/09/2025 | By Dineshwori | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy